Author’s response to reviews

Title: IL-10+ NK and TGF-β+ NK cells play negative regulatory roles in HIV infection

Authors:

Yongjun Jiang (jiangjun55555@163.com)
Mei Yang (1285175459@qq.com)
Xiaojuan Sun (364010041@qq.com)
Xi Chen (chenxi9204@yeah.net)
Meichen Ma (maomaochong432@163.com)
XiaoWan Yin (yinxiaowan1013@163.com)
Shi Qian (poem.z@163.com)
Zining Zhang (zi_ning101@hotmail.com)
Yajing Fu (fufu80s@sina.com)
Jing Liu (lj_sycmu@163.com)
Xiaoxu Han (xxhan@yeah.net)
Junjie Xu (xjjbeijing@gmail.com)
Hong Shang (hongshang100@hotmail.com)

Version: 2 Date: 18 Jan 2018

Author’s response to reviews:

1) After the list of abbreviations, please add the heading "Declarations", followed by the sub-headings listed below in the following order:

- Ethics approval and consent to participate

- Consent to publish

- Availability of data and materials

- Competing interests
Response:

We have reordered the manuscript, and added the heading "Declarations" in the line 295 on page 14.

2) Under the heading "Ethics approval and consent to participate", in addition to the name of the ethics committee that approved the study, if possible, please provide the reference number. Also, please confirm whether the patients provided written informed consent to participate in the study. If so, please state: "Written informed consent to participate in the study was obtained from all participants".

Response:

The Medical Science Research Ethics Committee of the First Affiliated Hospital of China Medical University approved our study, and the reference number is KELUNSHEN [2011] no.36. We have confirmed that all the patients in our study had written informed consent. All the above information were stated in our manuscript in the line 297-300 on page 14.

3) Under the heading "Funding", please describe the role of the funding body in the design of the study and collection, analysis, and interpretation of data.

Response:

We have described that the funding bodies had no roles in the design of the study and collection, analysis, and interpretation of data in the line 312-315 on page 14.
4) Under the heading "Authors' Contributions" you used three initials for most aus, yet on the title page, most names are missing out the middle name. Please make sure the full names and the initials in the Authors' Contributions match.

Response:
We have checked all the authors’ name in our paper, and have make sure the full names and the initials in the Authors' Contributions are now matching in the line 318-321 on page 15.

5) On uploading your revisions, please remove any tracked changes or highlighting and include only a single clean copy of the manuscript.

Response:
According to the reviewer’s comments, we have uploaded a clean copy of the manuscript on line.

6) Some better characterization of the ART treated group would be useful, in particular what is the definition of “undetectable” viral load used (<400, <200, <50 HIV RNA copies/mL?) and what was the median (IQR) duration of their virologic suppression at the time of the sampling (i.e. for how long had they been virologically suppressed)

Response:
We have defined the concept of viral load “undetectable” was HIV RNA <20 copies/mL, and we have labeled it in the Table 1, and the median duration of their virologic suppression at the time of the sampling was 33 months (IQR: 24-60 months). All the above information was stated it in our manuscript in the line 115-117 on page 5.
7) The manuscript requires some English language revision throughout

Response:

After completing our revision, we sent our revision to the language polishing company, Charlesworth Group (UK) to make our English language better.